Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027BRIDGEWATER, ...

Amneal Pharma receives US FDA approval for denosumab biosimilars Prolia and Xgeva: Bridgewater, New Jersey Friday, December 26, 2025, 16:00 Hrs [IST] Bridgewater headquartered Amn ...

FDA approval based on robust clinical studies and totality of evidence, which show no clinically meaningful differences from reference medicines Keren Haruvi, President Sandoz North America, said: ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the RANK ligand inhibitor can be challenging to navigate. "I don't think we have ...

Adding romosozumab to ongoing denosumab treatment shows increased lumbar spine bone mineral density with preserved anabolic ...

Please provide your email address to receive an email when new articles are posted on . “Although we observed an increasing number of osteonecrosis of the jaw cases in our daily practice during the ...

Sandoz shared that it has reached agreement with Amgen to resolve all patent disputes between the two companies relating to the Food and Drug Administration approved Sandoz denosumab biosimilars.

Among 1,032 Japanese patients on dialysis who started treatment for osteoporosis, denosumab use had a 45% lower risk for a composite of all fractures compared with oral bisphosphonates over 3 years ...

(HealthDay News) – Denosumab does not appear to delay fracture healing or contribute to other complications when used to treat postmenopausal women with osteoporosis, according to research published ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

Results of a large phase III randomized controlled trial—recently published online in the Lancet—have shown that denosumab can delay the onset of bone metastasis in patients with castration-resistant ...